Journal
JOURNAL OF CLINICAL MEDICINE
Volume 11, Issue 1, Pages -Publisher
MDPI
DOI: 10.3390/jcm11010222
Keywords
leucine aminopeptidase; ovarian cancer; urine biomarker; placenta
Categories
Ask authors/readers for more resources
A higher activity of P-LAP was found in the urine of ovarian cancer patients compared to patients with benign or borderline malignant tumors. A cut-off value of 11.00 U/L for P-LAP showed a sensitivity of 77.8% and a specificity of 95.5% in distinguishing invasive cancer.
Background: A non-invasive and sensitive biomarker for the detection of ovarian cancer (OvCa) is lacking. We aim to investigate if urinary placental leucine aminopeptidase (P-LAP) can serve as a reliable biomarker for OvCa. Methods: P-LAP activity was measured using a LAP assay kit (Serotech Co., Ltd., Sapporo, Japan) in the urine of 22 patients with benign or borderline malignant ovarian tumors and 18 patients with OvCa. In this assay, L-methionine was added at 20 mM because P-LAP is functional, but other aminopeptidases are inhibited at this dose of L-methionine. Results: The mean urinary P-LAP activity was significantly higher in the OvCa group than in the benign or borderline malignant tumor group. When the cut-off value of P-LAP was determined as 11.00 U/L, its sensitivity and specificity for differentiating invasive cancer were 77.8% and 95.5%, respectively. Conclusion: Although the usefulness of this test should be confirmed in a larger cohort of cases and controls, our study is the first to highlight the importance of urinary P-LAP as a biomarker for OvCa.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available